Dr. Reddy’s stock faces setback as Health Canada issues notice on Semaglutide
NegativeFinancial Markets

Dr. Reddy's Laboratories is facing a setback as Health Canada has issued a notice regarding its semaglutide product. This development is significant as semaglutide is a key medication for managing diabetes and obesity, and any regulatory issues can impact the company's market position and investor confidence.
— Curated by the World Pulse Now AI Editorial System





